15 results on '"Mulligan, Mark J."'
Search Results
2. The imperative of influenza vaccines for elderly individuals - an evolving story
- Author
-
Poland, Gregory A. and Mulligan, Mark J.
- Subjects
Influenza vaccines -- Usage ,Aged patients -- Care and treatment ,Influenza -- Reports ,Influenza -- Demographic aspects ,Influenza -- Prognosis ,Influenza -- Care and treatment ,Health - Published
- 2009
3. Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine.
- Author
-
Levin, Myron J., Guang-Yun Cai, Lee, Katherine S., Rouphael, Nadine G., Mehta, Aneesh K., Canniff, Jennifer, Mulligan, Mark J., Weinberg, Adriana, and Cai, Guang-Yun
- Subjects
VARICELLA-zoster virus ,HERPES zoster vaccines ,VIREMIA ,POLYMERASE chain reaction ,DNA virus diseases ,IMMUNE response ,HERPES zoster prevention ,T cells ,DNA ,HERPES zoster ,HERPESVIRUSES ,VACCINES ,VIRAL antibodies ,PHYSIOLOGY - Abstract
We studied the relationship between varicella-zoster virus (VZV) DNAemia and development of VZV-specific immunity after administration of live-attenuated zoster vaccine. VZV-DNAemia, detected by polymerase chain reaction (PCR), and VZV-specific effector (Teff) and memory (Tmem) T cells, was measured in 67 vaccinees. PCR was positive in 56% (9 direct, 28 nested) on day 1 and in 16% (1 direct, 10 nested) on day 14. Teff progressively increased in direct-PCR-positive vaccinees up to day 30, but Tmem did not. Conversely, Tmem, but not Teff, increased in direct-PCR-negative vaccinees on day 7. The kinetics of these immune responses and VZV DNAemia suggested that direct-PCR sample positive represented viremia. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
4. Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083
- Author
-
Walsh, Stephen R., primary, Moodie, Zoe, additional, Fiore-Gartland, Andrew J., additional, Morgan, Cecilia, additional, Wilck, Marissa B., additional, Hammer, Scott M., additional, Buchbinder, Susan P., additional, Kalams, Spyros A., additional, Goepfert, Paul A., additional, Mulligan, Mark J., additional, Keefer, Michael C., additional, Baden, Lindsey R., additional, Swann, Edith M., additional, Grant, Shannon, additional, Ahmed, Hasan, additional, Li, Fusheng, additional, Hertz, Tomer, additional, Self, Steven G., additional, Friedrich, David, additional, Frahm, Nicole, additional, Liao, Hua-Xin, additional, Montefiori, David C., additional, Tomaras, Georgia D., additional, McElrath, M. Juliana, additional, Hural, John, additional, Graham, Barney S., additional, and Jin, Xia, additional
- Published
- 2015
- Full Text
- View/download PDF
5. Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old
- Author
-
Keitel, Wendy A., primary, Jackson, Lisa A., additional, Edupuganti, Srilatha, additional, Winokur, Patricia L., additional, Mulligan, Mark J., additional, Thornburg, Natalie J., additional, Patel, Shital M., additional, Rouphael, Nadine G., additional, Lai, Lilin, additional, Bangaru, Sandhya, additional, McNeal, Monica M., additional, Bellamy, Abbie R., additional, and Hill, Heather R., additional
- Published
- 2015
- Full Text
- View/download PDF
6. Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.
- Author
-
Janes, Holly E., Cohen, Kristen W., Frahm, Nicole, De Rosa, Stephen C., Sanchez, Brittany, Hural, John, Magaret, Craig A., Karuna, Shelly, Bentley, Carter, Gottardo, Raphael, Finak, Greg, Grove, Douglas, Shen, Mingchao, Graham, Barney S., Koup, Richard A., Mulligan, Mark J., Koblin, Beryl, Buchbinder, Susan P., Keefer, Michael C., and Adams, Elizabeth
- Subjects
T cells ,DNA ,HIV ,VACCINATION ,IMMUNE response ,HIV prevention ,AIDS vaccines ,ANALYSIS of variance ,COMPARATIVE studies ,CYTOKINES ,GENES ,HIV infections ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,RESEARCH funding ,VIRUSES ,BIOINFORMATICS ,EVALUATION research ,RANDOMIZED controlled trials ,RELATIVE medical risk - Abstract
Background: It is important to identify vaccine-induced immune responses that predict the preventative efficacy of a human immunodeficiency virus (HIV)-1 vaccine. We assessed T-cell response markers as correlates of risk in the HIV Vaccine Trials Network (HVTN) 505 HIV-1 vaccine efficacy trial.Methods: 2504 participants were randomized to DNA/rAd5 vaccine or placebo, administered at weeks 0, 4, 8, and 24. Peripheral blood mononuclear cells were obtained at week 26 from all 25 primary endpoint vaccine cases and 125 matched vaccine controls, and stimulated with vaccine-insert-matched peptides. Primary variables were total HIV-1-specific CD4+ T-cell magnitude and Env-specific CD4+ polyfunctionality. Four secondary variables were also assessed. Immune responses were evaluated as predictors of HIV-1 infection among vaccinees using Cox proportional hazards models. Machine learning analyses identified immune response combinations best predicting HIV-1 infection.Results: We observed an unexpectedly strong inverse correlation between Env-specific CD8+ immune response magnitude and HIV-1 infection risk (hazard ratio [HR] = 0.18 per SD increment; P = .04) and between Env-specific CD8+ polyfunctionality and infection risk (HR = 0.34 per SD increment; P < .01).Conclusions: Further research is needed to determine if these immune responses are predictors of vaccine efficacy or markers of natural resistance to HIV-1 infection. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
7. Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.
- Author
-
Walsh, Stephen R., Moodie, Zoe, Fiore-Gartland, Andrew J., Morgan, Cecilia, Wilck, Marissa B., Hammer, Scott M., Buchbinder, Susan P., Kalams, Spyros A., Goepfert, Paul A., Mulligan, Mark J., Keefer, Michael C., Baden, Lindsey R., Swann, Edith M., Grant, Shannon, Ahmed, Hasan, Fusheng Li, Hertz, Tomer, Self, Steven G., Friedrich, David, and Frahm, Nicole
- Subjects
HIV ,VIRAL vaccines ,ADENOVIRUSES ,VACCINATION ,T cells ,AIDS vaccines ,ANTIGENS ,COMPARATIVE studies ,DRUG delivery systems ,GENES ,IMMUNIZATION ,RESEARCH methodology ,MEDICAL cooperation ,MEDICAL protocols ,PROTEINS ,RESEARCH ,RESEARCH funding ,VIRAL antigens ,VIRUSES ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,BLIND experiment - Abstract
Background: Increasing the breadth of human immunodeficiency virus type 1 (HIV-1) vaccine-elicited immune responses or targeting conserved regions may improve coverage of circulating strains. HIV Vaccine Trials Network 083 tested whether cellular immune responses with these features are induced by prime-boost strategies, using heterologous vectors, heterologous inserts, or a combination of both.Methods: A total of 180 participants were randomly assigned to receive combinations of adenovirus vectors (Ad5 or Ad35) and HIV-1 envelope (Env) gene inserts (clade A or B) in a prime-boost regimen.Results: T-cell responses to heterologous and homologous insert regimens targeted a similar number of epitopes (ratio of means, 1.0; 95% confidence interval [CI], .6-1.6; P = .91), but heterologous insert regimens induced significantly more epitopes that were shared between EnvA and EnvB than homologous insert regimens (ratio of means, 2.7; 95% CI, 1.2-5.7; P = .01). Participants in the heterologous versus homologous insert groups had T-cell responses that targeted epitopes with greater evolutionary conservation (mean entropy [±SD], 0.32 ± 0.1 bits; P = .003), and epitopes recognized by responders provided higher coverage (49%; P = .035). Heterologous vector regimens had higher numbers of total, EnvA, and EnvB epitopes than homologous vector regimens (P = .02, .044, and .045, respectively).Conclusions: These data demonstrate that vaccination with heterologous insert prime boosting increased T-cell responses to shared epitopes, while heterologous vector prime boosting increased the number of T-cell epitopes recognized.Clinical Trials Registration: NCT01095224. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
8. Impact of Adjuvants on the Immunogenicity and Efficacy of Split-Virion H7N9 Vaccine in Ferrets.
- Author
-
Keitel, Wendy A., Jackson, Lisa A., Edupuganti, Srilatha, Winokur, Patricia L., Mulligan, Mark J., Thornburg, Natalie J., Patel, Shital M., Rouphael, Nadine G., Lilin Lai, Bangaru, Sandhya, McNeal, Monica M., Bellamy, Abbie R., and Hill, Heather R.
- Subjects
INFLUENZA A virus, H3N2 subtype ,VIRUS disease transmission ,VIRAL disease treatment ,VIRAL vaccines ,IMMUNE response ,B cells ,IMMUNIZATION ,VACCINES - Abstract
Background. An effective vaccine is urgently needed against the H7N9 avian influenza virus. We evaluated the immunogenicity and protective efficacy of a split-virion H7N9 vaccine with or without the oil-in-water adjuvants in ferrets. Methods. Ferrets were vaccinated with 2 doses of unadjuvanted, MF59 or AS03-adjuvanted A/Shanghai/2/2013 (H7N9) vaccine, and the induction of antibodies to hemagglutinin (HA) or neuraminidase proteins was evaluated. Ferrets were then challenged with wild-type H7N9 virus to assess the vaccine's protective efficacy. The vaccine composition and integrity was also evaluated in vitro. Results. Adjuvanted vaccines stimulated robust serum antibody titers against HA and neuraminidase compared with the unadjuvanted vaccines. Although there was a difference in adjuvanticity between AS03 and MF59 at a lower dose (3.75 µg of HA), both adjuvants induced comparable antibody responses after 2 doses of 15 µg. On challenge, ferrets that received adjuvanted vaccines showed lower viral burden than the control or unadjuvanted vaccine group. In vitro examinations revealed that the vaccine contained visible split-virus particles and retained the native conformation of HA recognizable by polyclonal and monoclonal antibodies. Conclusions. The adjuvanted H7N9 vaccines demonstrated superior immunogenicity and protective efficacy against H7N9 infection in ferrets and hold potential as a vaccination regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
- Author
-
Goepfert, Paul A., Elizaga, Marnie L., Seaton, Kelly, Tomaras, Georgia D., Montefiori, David C., Sato, Alicia, Hural, John, DeRosa, Stephen C., Kalams, Spyros A., McElrath, M. Juliana, Keefer, Michael C., Baden, Lindsey R., Lama, Javier R., Sanchez, Jorge, Mulligan, Mark J., Buchbinder, Susan P., Hammer, Scott M., Koblin, Beryl A., Pensiero, Michael, and Butler, Chris
- Subjects
DRUG delivery systems ,PROTEINS ,VIRAL vaccines ,VIRUSES ,TIME ,AIDS vaccines ,PLACEBOS ,RANDOMIZED controlled trials ,RESEARCH funding ,VIRAL antibodies ,T cells ,HIV - Abstract
Background: Clade B DNA and recombinant modified vaccinia Ankara (MVA) vaccines producing virus-like particles displaying trimeric membrane-bound envelope glycoprotein (Env) were tested in a phase 2a trial in human immunodeficiency virus (HIV)-uninfected adults for safety, immunogenicity, and 6-month durability of immune responses.Methods: A total of 299 individuals received 2 doses of JS7 DNA vaccine and 2 doses of MVA/HIV62B at 0, 2, 4, and 6 months, respectively (the DDMM regimen); 3 doses of MVA/HIV62B at 0, 2, and 6 months (the MMM regimen); or placebo injections.Results: At peak response, 93.2% of the DDMM group and 98.4% of the MMM group had binding antibodies for Env. These binding antibodies were more frequent and of higher magnitude for the transmembrane subunit (gp41) than the receptor-binding subunit (gp120) of Env. For both regimens, response rates were higher for CD4(+) T cells (66.4% in the DDMM group and 43.1% in the MMM group) than for CD8(+) T cells (21.8% in the DDMM group and 14.9% in the MMM group). Responding CD4(+) and CD8(+) T cells were biased toward Gag, and >70% produced 2 or 3 of the 4 cytokines evaluated (ie, interferon γ, interleukin 2, tumor necrosis factor α, and granzyme B). Six months after vaccination, the magnitudes of antibodies and T-cell responses had decreased by <3-fold.Conclusions: DDMM and MMM vaccinations with virus-like particle-expressing immunogens elicited durable antibody and T-cell responses. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
10. Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons.
- Author
-
Jackson, Lisa A., Chen, Wilbur H., Stapleton, Jack T., Dekker, Cornelia L., Wald, Anna, Brady, Rebecca C., Edupuganti, Srilatha, Winokur, Patricia, Mulligan, Mark J., Keyserling, Harry L., Kotloff, Karen L., Rouphael, Nadine, Noah, Diana L., Hill, Heather, and Wolff, Mark C.
- Subjects
INFLUENZA vaccination research ,INFLUENZA prevention ,BLOOD agglutination ,H1N1 influenza ,VIRAL vaccines ,IMMUNE response ,VACCINATION - Abstract
Background. Adjuvanted vaccines have the potential to improve influenza pandemic response. AS03 adjuvant has been shown to enhance the immune response to inactivated influenza vaccines.Methods. This trial was designed to evaluate the immunogenicity and safety of an inactivated 2009 H1N1 influenza vaccine at varying dosages of hemagglutinin with and without extemporaneously mixed AS03 adjuvant system in adults ≥18 years of age. Adults were randomized to receive 2 doses of 1 of 5 vaccine formulations (3.75 µg, 7.5 µg, or 15 µg with AS03 or 7.5 µg or 15 µg without adjuvant).Results. The study population included 544 persons <65 years of age and 245 persons ≥65 years of age. Local adverse events tended to be more frequent in the adjuvanted vaccine groups, but severe reactions were uncommon. In both age groups, hemagglutination inhibition antibody geometric mean titers after dose one were higher in the adjuvanted groups, compared with the 15 µg unadjuvanted group, and this difference was statistically significant for the comparison of the 15 µg adjuvanted group with the 15 µg unadjuvanted group.Conclusions. AS03 adjuvant system improves the immune response to inactivated 2009 H1N1 influenza vaccine in both younger and older adults and is generally well tolerated.ClinicalTrials.gov NCT00963157 [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
11. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.
- Author
-
Belshe RB, Frey SE, Graham I, Mulligan MJ, Edupuganti S, Jackson LA, Wald A, Poland G, Jacobson R, Keyserling HL, Spearman P, Hill H, Wolff M, National Institute of Allergy and Infectious Diseases-Funded Vaccine and Treatment Evaluation Units, Belshe, Robert B, Frey, Sharon E, Graham, Irene, Mulligan, Mark J, Edupuganti, Srilatha, and Jackson, Lisa A
- Abstract
Background: The current US national stockpile of influenza H5 vaccine was produced using the antigen from the strain A/Vietnam/1203/2004 (a clade 1 H5 virus). Recent H5 disease has been caused by antigenically divergent H5 viruses, including A/Indonesia/05/2005 (a clade 2 H5 virus).Methods: The influence of schedule on the antibody response to 2 doses of H5 vaccines (one a clade 1 hemagglutinin protein [HA] vaccine and one a clade 2 HA vaccine) containing 90 μg of antigen was evaluated in healthy adults 18-49 years of age.Results: Two doses of vaccine were required to induce antibody titers ≥ 1:10 in most subjects. Accelerated schedules were immunogenic, and antibody developed after vaccinations on days 0 and 7, 0 and 14, and 0 and 28, with the day 0 and 7 schedule inducing lower titers than those induced with the other schedules. With mixed vaccine schedules of clade 1 followed by clade 2 vaccine administration, the first vaccination primed for a heterologous boost. The heterologous response was improved when the second vaccination was given 6 months after the first, compared with the response when the second vaccination was given after an interval of 1 month.Conclusions: An accelerated vaccine schedule of injections administered at days 0 and 14 was as immunogenic as a vaccine schedule of injections at days 0 and 28, but both schedules were inferior to a vaccine schedule of injections administered at 0 and 6 months for priming for heterologous vaccine boosting. Clinical Trial Registry Number: NCT00703053. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
12. A Canarypox Vaccine Expressing Multiple Human Immunodeficiency Virus Type 1 Genes Given Alone or with Rgp120 Elicits Broad and Durable CD8[sup+] Cytotoxic T Lymphocyte Responses in Seronegative Volunteers.
- Author
-
Evans, Thomas G., Keefer, Michael C., Weinhold, Kent J., Wolff, Mark, Montefiori, David, Gorse, Geoffrey J., Graham, Barney S., McElrath, M. Juliana, Clements-Mann, Mary Lou, Mulligan, Mark J., Fast, Patricia, Walker, Mary Clare, Excler, Jean-Louis, Duliege, Ann-Marie, and Tartaglia, James
- Subjects
VIRAL vaccines ,HIV - Abstract
Examines a canarypox vaccine expressing multiple HIV-1 genes. Advantages of canarypox vaccine; Role of T cell in measuring lymphoproliferation; Response of cytotoxic T lymphocytes on the components of the vaccine.
- Published
- 1999
- Full Text
- View/download PDF
13. Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines.
- Author
-
Graham, Barney S., McElrath, M. Juliana, Connor, Ruth I., Schwartz, David H., Gorse, Geoffrey J., Keefer, Michael C., Mulligan, Mark J., Matthews, Thomas J., Wolinsky, Steven M., Montefiori, David C., Vermund, Sten H., Lambert, John S., Corey, Lawrence, Belshe, Robert B., Dolin, Raphael, Wright, Peter F., Korber, Bette T., Wolff, Mark C., and Fast, Patricia E.
- Abstract
Among 2099 uninfected subjects in phase I and II trials of candidate AIDS vaccines, 23 were diagnosed with intercurrent human immunodeficiency virus type 1 (HIV-1) infection. High-risk sexual exposures accounted for 17 infections, and intravenous drug use accounted for 6. Four subjects received placebo, 13 received a complete immunization schedule (⩾3 injections), and 6 were partially immunized (⩽2 injections). There was no significant difference between vaccine recipients and control groups in incidence of HIV-1 infection, virus load, CD4 lymphocyte count, or V3 loop amino acid sequence. In summary, 19 vaccinated subjects acquired HIV-1 infection during phase I and II trials, indicating that immunization with the products described is <100% effective in preventing or rapidly clearing infection. Laboratory analysis suggested that vaccineinduced immune responses did not significantly affect the genotypic or phenotypic characteristics of transmitted virus or the early clinical course of HIV-1 infection. [ABSTRACT FROM PUBLISHER]
- Published
- 1998
- Full Text
- View/download PDF
14. Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
- Author
-
Blazevic A, Edwards RL, Xia M, Eickhoff CS, Hamzabegovic F, Meza KA, Ning H, Tennant J, Mosby KJ, Ritchie JC, Girmay T, Lai L, McCullough M, Beck A, Kelley C, Edupuganti S, Kabbani S, Buchanan W, Makhene MK, Voronca D, Cherikh S, Goll JB, Rouphael NG, Mulligan MJ, and Hoft DF
- Subjects
- Humans, Male, Adult, Female, Young Adult, Mycobacterium bovis immunology, Middle Aged, Mycobacterium tuberculosis immunology, Injections, Intradermal, Adolescent, Dose-Response Relationship, Immunologic, BCG Vaccine immunology, BCG Vaccine administration & dosage, Tuberculosis prevention & control, Tuberculosis immunology
- Abstract
Background: A controlled human infection model for assessing tuberculosis (TB) immunity can accelerate new vaccine development., Methods: In this phase 1 dose escalation trial, 92 healthy adults received a single intradermal injection of 2 × 106 to 16 × 106 colony-forming units of Bacillus Calmette-Guérin (BCG). The primary endpoints were safety and BCG shedding as measured by quantitative polymerase chain reaction, colony-forming unit plating, and MGIT BACTEC culture., Results: Doses up to 8 × 106 were safe, and there was evidence for increased BCG shedding with dose escalation. The MGIT time-to-positivity assay was the most consistent and precise measure of shedding. Power analyses indicated that 10% differences in MGIT time to positivity (area under the curve) could be detected in small cohorts (n = 30). Potential biomarkers of mycobacterial immunity were identified that correlated with shedding. Transcriptomic analysis uncovered dose- and time-dependent effects of BCG challenge and identified a putative transcriptional TB protective signature. Furthermore, we identified immunologic and transcriptomal differences that could represent an immune component underlying the observed higher rate of TB disease incidence in males., Conclusions: The safety, reactogenicity, and immunogenicity profiles indicate that this BCG human challenge model is feasible for assessing in vivo TB immunity and could facilitate the vaccine development process., Clinical Trials Registration: NCT01868464 (ClinicalTrials.gov)., Competing Interests: Potential conflicts of interest. D. F. H. receives personal fees for scientific advisory board service for Moderna and Poolbeg Pharma; M. J. M. performs laboratory research and holds clinical trials contracts with Lilly, Pfizer, and Sanofi and receives personal fees for scientific advisory board service from Merck, Meissa Vaccines, Inc, and Pfizer; N. G. R. receives funding from Merck, Sanofi Pasteur, Pfizer, Lilly, and Quidel to perform clinical research and serves as a safety consultant for ICON and Emmes LCC. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
15. Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum.
- Author
-
Rouphael N, Beck A, Kirby AE, Liu P, Natrajan MS, Lai L, Phadke V, Winston J, Raabe V, Collins MH, Girmay T, Alvarez A, Beydoun N, Karmali V, Altieri-Rivera J, Lindesmith LC, Anderson EJ, Wang Y, El-Khorazaty J, Petrie C, Baric RS, Baqar S, Moe CL, and Mulligan MJ
- Subjects
- Adult, Humans, Diarrhea, Genotype, Immunoglobulin G, Norovirus genetics, Caliciviridae Infections, Gastroenteritis
- Abstract
Background: Genogroup II noroviruses are the most common cause of acute infectious gastroenteritis. We evaluated the use of a new GII.2 inoculum in a human challenge., Methods: Forty-four healthy adults (36 secretor-positive and 8 secretor-negative for histo-blood group antigens) were challenged with ascending doses of a new safety-tested Snow Mountain virus (SMV) GII.2 norovirus inoculum (1.2 × 104 to 1.2 × 107 genome equivalent copies [GEC]; n = 38) or placebo (n = 6). Illness was defined as diarrhea and/or vomiting postchallenge in subjects with evidence of infection (defined as GII.2 norovirus RNA detection in stool and/or anti-SMV immunoglobulin G [IgG] seroconversion)., Results: The highest dose was associated with SMV infection in 90%, and illness in 70% of subjects with 10 of 12 secretor-positive (83%) and 4 of 8 secretor-negative (50%) becoming ill. There was no association between prechallenge anti-SMV serum IgG concentration, carbohydrate-binding blockade antibody, or salivary immunoglobulin A and infection. The median infectious dose (ID50) was 5.1 × 105 GEC., Conclusions: High rates of infection and illness were observed in both secretor-positive and secretor-negative subjects in this challenge study. However, a high dose will be required to achieve the target of 75% illness to make this an efficient model for evaluating potential norovirus vaccines and therapeutics., Clinical Trials Registration: NCT02473224., Competing Interests: Potential conflicts of interest. N. R. has research support from Merck, Sanofi Pasteur, Lilly, Quidel, Pfizer and do not pose a conflict of interest for this paper. M. J. M. has research support from Lilly, Pfizer, Sanofi; personal fees from Pfizer and Meissa Vaccines and do not pose a conflict of interest for this paper. L. C. L. and R. S. B. have ongoing collaborations with Hillvax, VaxArt and Takeda that are unrelated and do not pose conflicts of interest with this report. C.L.M has collaborations with Takeda that are unrelated and do not pose conflicts of interest with this report. V. R. has research support from Sanofi Pasteur, unrelated, no conflict of interest with this report. E. J. A. has consulted for Pfizer, Sanofi Pasteur, Janssen, and Medscape, and his institution receives funds to conduct clinical research unrelated to this manuscript from MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Sanofi-Pasteur, Janssen, and Micron. He also serves on a safety monitoring board for Kentucky BioProcessing, Inc. and Sanofi Pasteur. No conflict of interest with this report. C. P., J. E. K., A. E. K., A. B., P. L., M. S. N., L. L., V. P., J. W., M. H. C., T. G., A. A., N. B., V. K., J. A. R., Y. W., and S. B. have no competing interests to declare. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.